Sanofi raised the company’s 2021 profit forecast on July 29 after its vaccines and star eczema treatment Dupixent helped the French drugmaker beat second-quarter results expectations.
If you are not happy with the results below please do another search
50 search results for:
Isolation and the absence of family and friends have taken a toll on athletes’ mental health at the Tokyo Olympics, with some struggling to cope with the challenges posed by the pandemic while carrying their country’s hopes on the global sports stage.
BioSpace takes a look at the flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites.
In order for healthcare organizations to create healthier communities, they need insight into more than clinical patient information. They also need to see behavioral health data, which is a major indicator of risk and trends for their population. Having access to this information can feed into more effective preventative and community-based mental health services and treatments for patients.
Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.
Pfizer Inc. on July 28 raised the 2021 sales forecast for the company’s Covid-19 vaccine by 29 percent to $33.5 billion, and said the drugmaker believes people will need a third dose of the shot developed with German partner BioNTech to keep protection against the virus high.
One month after GlaxoSmithKline outlined plans for the company’s future following a planned split between its pharmaceuticals and consumer health businesses, GSK posted second-quarter 2021 sales of £8.1 billion ($11.2 billion).
Biogen reportedly withdrew a paper that analyzed data from the clinical trials of the Alzheimer’s drug Aduhelm that the company submitted to JAMA after the medical journal requested edits before publication.
Amgen is snapping up privately held Teneobio and the company’s class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.5 billion.
Bristol Myers Squibb Co. reported second-quarter 2021 earnings that topped Wall Street estimates, as sales of the company’s flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.